Is the future of diabetes drugs in dual GIP and GLP-1 incretin receptor agonists? That’s the $47M question for Carmot

Nearly three years after closing its Series B, Carmot Therapeutics has returned to the fundraising well with a new round. And this time they brought pharma giant Amgen into the fold. The Berkeley, CA-based biotech announced Thursday the completion of $47 million in Series C financing to boost development of…

Click to view original post